Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients

Avanir Pharmaceuticals, a US subsidiary of Otsuka Pharmaceutical, said on September 27 that its investigational agent AVP-786 (deudextromethorphan hydrobromide + quinidine sulfate) has failed to demonstrate a statistically significant improvement in symptoms of agitation in patients with Alzheimer’s disease (AD)...read more